Welcome to our dedicated page for Adaptimmune Therapeutics Plc news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics Plc stock.
Adaptimmune Therapeutics PLC (ADAP) is a clinical-stage biopharmaceutical leader developing T-cell receptor therapies for solid tumor cancers. This page serves as the definitive source for verified company news and press releases, providing stakeholders with timely updates on clinical developments and corporate milestones.
Investors and researchers will find essential information including trial progress reports, regulatory filings, and partnership announcements. Our curated collection features:
• Clinical trial updates for engineered T-cell therapies
• Strategic collaboration announcements with industry partners
• Financial performance disclosures and SEC filings
• Scientific presentations at major medical conferences
Bookmark this page for direct access to Adaptimmune's latest advancements in TCR technology and immuno-oncology research. Check regularly for authoritative updates on pipeline developments and operational progress.
Adaptimmune Therapeutics (NASDAQ: ADAP) provided its Q4 and Full Year 2024 business update, highlighting progress in its sarcoma franchise. TECELRA®, their first commercial product, shows increasing momentum with 10 patients apheresed in Q1 2025 and 3 in 2024. The company has activated 20 Authorized Treatment Centers (ATCs) and achieved Q4 product revenue of $1.2m.
Their second product, lete-cel, met its pivotal trial primary endpoint with 42% ORR and is on track for BLA submission in late 2025, with anticipated approval in 2026. The company executed a 29% headcount reduction in Q1 2025, targeting approximately $300 million in cost savings over four years to achieve operating profitability by 2027.
However, Adaptimmune disclosed substantial doubt about their ability to continue as a going concern in their upcoming 2024 Annual Report. The company reported Total Liquidity of $152 million at the end of 2024 and has engaged TD Cowen to evaluate strategic options.
Adaptimmune Therapeutics (NASDAQ: ADAP), a cell therapy company focused on solid tumor cancers, has scheduled its Q4 and Full Year 2024 financial results and business updates announcement for Thursday, March 20, 2025, before US markets open.
The company will host a live webcast at 8:00 a.m. EDT on the same day. Investors can access the press release through Adaptimmune's corporate website's investor section and join the webcast at https://www.gowebcasting.com/13966. Call-in options are available at 1-833-821-0158 (US/Canada) or 1-647-846-2266 (International), with participants advised to dial in 5-10 minutes before the scheduled start.
Adaptimmune Therapeutics (NASDAQ: ADAP), a pioneer in solid tumor cancer cell therapy treatments, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York, NY. The company's CEO, Adrian Rawcliffe, will engage in a fireside chat on February 6, 2025, at 3:00 p.m. EST.
The event will be accessible via webcast, and interested parties can join through the provided link or through the 'Events' section under the 'News Center' tab in the 'Investors & Media' area of Adaptimmune's website. A replay of the presentation will be available after the event.
Adaptimmune Therapeutics (NASDAQ: ADAP) announced that its therapy letetresgene autoleucel (lete-cel) has received FDA breakthrough therapy designation for treating myxoid/round cell liposarcoma (MRCLS) in specific patient conditions. The designation was based on Phase II IGNYTE-ESO trial results, where 42% of patients (27/64) with synovial sarcoma or MRCLS showed responses, including 6 complete and 21 partial responses.
The median duration of response was 12.2 months overall, with 18.3 months for synovial sarcoma and 12.2 months for MRCLS patients. Safety findings showed manageable toxicities, with common adverse events including cytopenias, cytokine release syndrome, and rash.
The breakthrough designation will expedite lete-cel's development and review processes, with Adaptimmune planning to initiate a rolling Biologics License Application later in 2025. The company aims to bring lete-cel to market in 2026 for both synovial sarcoma and MRCLS treatment.
Adaptimmune Therapeutics (NASDAQ: ADAP) announced key executive departures as part of its ongoing restructuring efforts. Helen Tayton-Martin, Co-Founder and Chief Business & Strategy Officer, will leave on March 31, 2025, while CFO Gavin Wood will depart on May 31, 2025. These changes align with the company's previously announced 33% headcount reduction and target of $300 million in cost savings over four years.
The company plans to concentrate more corporate functions in the US. Tayton-Martin, who co-founded Adaptimmune in 2008, played a important role in growing the company from 5 to 300 employees and oversaw various strategic initiatives. Wood, who joined in 2020, led financial operations through successful financings and the approval of their first commercial product, Tecelra.
Adaptimmune Therapeutics has announced the treatment of its first patient with TECELRA® at Moffitt Cancer Center. This marks a significant milestone as TECELRA becomes the first FDA-approved engineered cell therapy for solid tumor cancer in the U.S., specifically for synovial sarcoma.
The FDA granted accelerated approval in August 2024 for TECELRA to treat adults with unresectable or metastatic synovial sarcoma who meet specific criteria, including prior chemotherapy and certain genetic markers. The treatment network includes several Authorized Treatment Centers across the US, with plans to expand to approximately 30 centers by the end of 2025, covering 80% of patients in sarcoma centers of excellence.
Adaptimmune Therapeutics (NASDAQ: ADAP) reports Q3 2024 updates with Total Liquidity of $186.1 million. The company announces a strategic restructuring with a planned 33% headcount reduction in Q1 2025, targeting approximately $300 million in cost savings over four years. The Tecelra® launch is progressing with 9 Authorized Treatment Centers, and the first patient has been apheresed. The company reports a 42% overall response rate in the lete-cel IGNYTE-ESO pivotal trial for synovial sarcoma and MRCLS. Q3 revenue was $40.9 million, and the company aims to achieve operating breakeven during 2027.
Adaptimmune Therapeutics (NASDAQ: ADAP) announced positive results from its pivotal Phase 2 IGNYTE-ESO trial of lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS). The trial achieved a 42% response rate (27/64 patients), including six complete responses and 21 partial responses. The median duration of response was 18.3 months for synovial sarcoma and 12.2 months for MRCLS. Based on these results, the company plans to initiate a rolling Biologics License Application submission by end of 2025.
Adaptimmune Therapeutics (NASDAQ: ADAP) has announced its participation in three major scientific conferences: SITC (November 6-10, Houston), CTOS (November 13-16, San Diego), and ASH (December 7-10, San Diego). The company will present research on cell therapies for solid tumors, particularly focusing on synovial sarcoma treatments.
Key presentations include data on afami-cel's anti-tumor activity, the IGNYTE-ESO trial results, and decentralized manufacturing processes. A notable virtual event is scheduled for November 18, featuring Dr. Sandra D'Angelo from Memorial Sloan Kettering Cancer Center, discussing the IGNYTE-ESO dataset and engineered cell therapies' impact on sarcoma treatment.
Adaptimmune Therapeutics (NASDAQ: ADAP), a cell therapy company focused on solid tumor cancers, will announce its Q3 2024 financial results and business updates after US markets close on November 13, 2024. The company will host a live webcast at 4:30 p.m. EDT (9:30 p.m. GMT). The press release will be available on Adaptimmune's corporate website, and investors can access the webcast through a provided link. Call-in options are available for US/Canada (+1-844-763-8274) and International (+1-647-484-8814) participants.
